Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistHekma Center, LLC was cited for marketing dietary supplement products (including formulations for anemia, diabetes, hypertension, cardiomyopathy, stroke, and multiple sclerosis) with disease treatment and prevention claims across their website and social media platforms, thereby causing the products to be classified as unapproved drugs under the Federal Food, Drug, and Cosmetic Act. The company violated FDA regulations by introducing these misbranded products into interstate commerce with claims such as "very potent in helping people with Anemia" and language indicating intended use for curing, mitigating, treating, or preventing specific diseases, rather than maintaining compliant dietary supplement labeling.